Ubs Group Ag Purple Biotech Ltd. Transaction History

Ubs Group Ag

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.41 - $0.86 $508 - $1,067	1,241 Added 10.69%	12,852 $5,000
Q1 2024 May 13, 2024	BUY	$0.58 - $0.92 $5,574 - $8,842	9,611 Added 480.55%	11,611 $7,000
Q4 2023 Feb 09, 2024	BUY	$0.78 - $1.67 $103 - $222	133 Added 7.12%	2,000 $1,000
Q3 2023 Nov 09, 2023	BUY	$1.02 - $1.49 $1,904 - $2,781	1,867 New	1,867 $2,000
Q1 2023 May 12, 2023	SELL	$1.36 - $2.3 $5,063 - $8,562	-3,723 Reduced 44.91%	4,566 $8,000
Q4 2022 Feb 08, 2023	SELL	$1.38 - $2.22 $3,089 - $4,970	-2,239 Reduced 21.27%	8,289 $11,000
Q3 2022 Nov 10, 2022	BUY	$1.9 - $2.69 $11,149 - $15,784	5,868 Added 125.92%	10,528 $21,000
Q2 2022 Aug 10, 2022	BUY	$2.39 - $4.15 $6,352 - $11,030	2,658 Added 132.77%	4,660 $11,000
Q1 2022 May 16, 2022	SELL	$2.45 - $4.3 $2,611 - $4,583	-1,066 Reduced 34.75%	2,002 $8,000
Q4 2021 Feb 14, 2022	SELL	$3.75 - $4.67 $3,791 - $4,721	-1,011 Reduced 24.79%	3,068 $12,000
Q3 2021 Nov 15, 2021	SELL	$4.4 - $5.59 $75,196 - $95,533	-17,090 Reduced 80.73%	4,079 $19,000
Q2 2021 Aug 13, 2021	BUY	$3.75 - $6.72 $11,227 - $20,119	2,994 Added 16.47%	21,169 $104,000
Q1 2021 May 12, 2021	SELL	$3.93 - $6.99 $9,872 - $17,558	-2,512 Reduced 12.14%	18,175 $75,000
Q4 2020 Feb 11, 2021	BUY	$3.81 - $4.73 $78,817 - $97,849	20,687 New	20,687 $79,000

Ticker PPBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,303,300
Market Cap $67M
Description
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhi...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.